JP4229973B2 - 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 - Google Patents
男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 Download PDFInfo
- Publication number
- JP4229973B2 JP4229973B2 JP2008016852A JP2008016852A JP4229973B2 JP 4229973 B2 JP4229973 B2 JP 4229973B2 JP 2008016852 A JP2008016852 A JP 2008016852A JP 2008016852 A JP2008016852 A JP 2008016852A JP 4229973 B2 JP4229973 B2 JP 4229973B2
- Authority
- JP
- Japan
- Prior art keywords
- scot
- polynucleotide
- dna
- male infertility
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000007466 Male Infertility Diseases 0.000 title claims description 33
- 230000035772 mutation Effects 0.000 title claims description 28
- 108090000623 proteins and genes Proteins 0.000 title claims description 22
- 238000002405 diagnostic procedure Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims description 63
- 108091033319 polynucleotide Proteins 0.000 claims description 51
- 102000040430 polynucleotide Human genes 0.000 claims description 51
- 239000002157 polynucleotide Substances 0.000 claims description 51
- 108091034117 Oligonucleotide Proteins 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 230000000295 complement effect Effects 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 108010038807 Oligopeptides Proteins 0.000 claims description 13
- 102000015636 Oligopeptides Human genes 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 239000013611 chromosomal DNA Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108020003215 DNA Probes Proteins 0.000 claims description 4
- 238000000018 DNA microarray Methods 0.000 claims description 4
- 239000003298 DNA probe Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 208000021267 infertility disease Diseases 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000001509 sodium citrate Substances 0.000 description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
- 229940038773 trisodium citrate Drugs 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 102000004357 Transferases Human genes 0.000 description 6
- 108090000992 Transferases Proteins 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- 101000716795 Homo sapiens Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial Proteins 0.000 description 5
- 102100020869 Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000002072 anti-mutant effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000001850 reproductive effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000021595 spermatogenesis Effects 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102100020868 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Human genes 0.000 description 2
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220328468 rs1555592021 Human genes 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000010079 Coenzyme A-Transferases Human genes 0.000 description 1
- 108010077385 Coenzyme A-Transferases Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101000716763 Homo sapiens Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710107852 Probable succinyl-CoA:3-ketoacid coenzyme A transferase subunit A Proteins 0.000 description 1
- 101710107846 Probable succinyl-CoA:3-ketoacid coenzyme A transferase subunit B Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 101710145888 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Proteins 0.000 description 1
- 101710091395 Succinyl-CoA:3-ketoacid coenzyme A transferase subunit A Proteins 0.000 description 1
- 101710091394 Succinyl-CoA:3-ketoacid coenzyme A transferase subunit B Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001463 effect on reproduction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000003313 haploid nucleated cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- -1 maleimide compound Chemical class 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 231100000527 sperm abnormality Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
Rubio C, et al. Human Reprod 2001; 10: 2084-2092 Lee PA, et al. (2000) J Urol., 164(5), 1697-1701 Cram DS, et al. (2001) J Androl 22(5), 738-746 Thielemans BFJ, et al. Eur. J. Obst Gynec 1998; 81: 217-225 Mitchell GA, et al. Clin. Invest. Med. 1995; 18: 193-216 Williamson, D. H., et al. (1971) Biochem. J., 121, 41-47 Tildon JT, et al. J Clinic Invest 1972; 51: 493-498 Lin, T. W. and Bridger, W. A. (1992) J. Biol. Chem., 267, 975-978 Kassovska-Bratinova S, et al. Am J Hum Genet 1996; 59: 519-528 Koga M, et al. Biol Reprod 2000; 63: 1601-1609 Rochet JC, Bridger WA. (1994) Protein Sci., 3, 975-81 Tanaka H, et al. Mol Human Reprod 2001; 8: 16-23 Pascual, M. I., et al. (1996) Biosci. Rep., 16, 35-40 Yeung, C. H., et al. (1996) Mol. Hum. Reprod., 2, 591-596 Ruiz-Pesini, E., et al.(1998) Clin. Chem., 44, 1616-1620
第129位tがcに置換;
第870位tがgに置換;
第1071位cがtに置換;および
第1667位tがcに置換
より選択される1以上の変異を有するポリヌクレオチド(Scot-t変異ポリヌクレオチド)またはその相補配列を提供する。
第38位LeuがProに置換;
第285位LeuがArgに置換;および
第352位ThrがMetに置換;
より選択される1以上の変位を有するポリペプチド(Scot-t変異ポリペプチド)を提供する。
第129位tがcに置換;
第870位tがgに置換;
第1071位cがtに置換;および
第1667位tがcに置換
のいずれか1以上を有するポリヌクレオチドまたはその相補配列である。
第38位LeuがProに置換;
第285位LeuがArgに置換;および
第352位ThrがMetに置換;
のいずれか1以上を有するポリペプチドである。
すなわち、これらのScot-t変異ポリペプチドは、前記発明のScot-t変異ポリヌクレオチドにおけるミスセンス変異によって、正常(野性型)ポリペプチド(配列番号2)のアミノ酸が前記のとおりに変異している。
1. 方法
1-1. 被験者とゲノムDNAの抽出
Scot-t遺伝子の分析には、合計255例の男性不妊患者を精液学に従って複数の下位群に分けた。152例(60%)は非閉塞性の無精子症であり、72例(28%)には重度の精子減少症(0.1から3×106細胞/ml)、27例(11%)は精子運動性が低く、4例(2%)が精子の数、形態および運動に異常がない特発性不妊症であった。対照群は、生殖可能な男性261例(産科医院を訪れた妊娠した妻の夫)を対象とした。
1-2. ヒトScot-tゲノムDNA中の変異同定
ヒトScot-tにはコーディング領域の中央部に19bpの欠失(745番から762番までの18個のヌクレオチドと、15個のヌクレオチドをはさんで778番の1個のヌクレオチド)を持つ偽遺伝子があるため(Tanaka H, et al. Mol Human Reprod 2001; 8: 16-23)、この欠失領域を含むPCRプライマーを2種類作成し、偽遺伝子が増幅されないようにした。すなわち、5'半分の増幅には推定転写開始部位の上流にある25個のオリゴヌクレオチド(tgctctgtgacgcgcggcccgaggc:配列番号3)と770番から745番までの26個のオリゴヌクレオチド(cctccacgatctcttccacctccacc:配列番号4)、741番から764番までの24子のオリゴヌクレオチド(cggtggaggtggaagagatcgtgg:配列番号5)、そしてh-Scot-t遺伝子の推定転写ユニットの下流にある25個のオリゴヌクレオチド(tccattcctcaccactgcacacctg:配列番号6)(図1参照)を用いた。
1-3. 組換えh-Scot-t cDNAの各種SNPタイプの遺伝子導入とスクシニルCoAトランスフェラーゼ活性分析
CaPO4を用いて各cDNAをトランスフェクションした72時間後に、HEK293細胞を溶解し、それぞれの細胞溶解液(5mgタンパク質)をHPLCを用いたクロマトグラフ処理に供して外因性SCOT-tと内因性SCOT-sを分離し、酵素活性分析を行った。スクシニルCoAトランスフェラーゼ活性の標準化は、抗SCOT-t抗体を用いたウェスタンブロッティングシグナルから濃度計により評価したh-SCOT-tタンパク質の相対量を用いて行った。
2. 結果
2-1. ヒトScot-t DNAの配列分析
前記1-2に記載したPCRプライマーの設定により、偽遺伝子DNAを増幅せず、真のScot-tゲノムDNAのみを増幅することによって、不妊の危険性がある男性と生殖能力の証明された対照男性との比較を行った。
h-SCOT-t酵素活性に対するSNPsの影響を調べるため、アミノ酸置換を生じる3箇所のSNPsを保有する組換えタンパク質をHEK293細胞中で発現させ、スクシニルCoAトランスフェラーゼ活性の分析をin vitroで行った。t129c(L38P)とc1392t(T352M)に位置するマイナー型のSNPsは、いずれもメジャー型SNPsと同様なレベルの酵素活性を示した。対照的にT870G(L285R)に位置するマイナー型(g/g)のSNPは、メジャー型と比較してin vitroで約半分ほど酵素活性を減少させた(表4)。この結果から、h-SCOT-tのスクシニルCoAトランスフェラーゼ活性が男性不妊の前提条件であり、酵素活性を減少させるSNPsの中には男性不妊の原因となるものが存在することが示される。
Claims (14)
- 男性不妊関連遺伝子Scot-tから転写されるmRNAに相補的なポリヌクレオチドであって、配列番号1のDNA配列において、以下の群:
第870位tがgに置換;および
第1667位tがcに置換
より選択される1以上の変異を有するポリヌクレオチドまたはその相補配列からなるポリヌクレオチド。 - 請求項1のポリヌクレオチドの一部であって、その変異箇所を含む20〜100の連続したDNA配列からなるオリゴヌクレオチドまたはその相補配列からなるオリゴヌクレオチド。
- 請求項1のポリヌクレオチドをPCR増幅するためのプライマーセットであって、一方のプライマーが、変異箇所を含む15〜30の連続したDNA配列またはその相補配列からなるオリゴヌクレオチドであるプライマーセット。
- 請求項1のポリヌクレオチドの発現産物であって、配列番号2のアミノ酸配列において、第285位LeuがArgに置換された変位を有するポリペプチド。
- 請求項4のポリペプチドの一部であって、変異箇所を含む5〜30の連続したアミノ酸配列からなるオリゴペプチド。
- 請求項5のオリゴペプチドを抗原として作製された抗体。
- 男性不妊の検査方法であって、被験者から単離した染色体DNA中に請求項1のポリヌクレオチドが存在するか否かを検出することを特徴とする方法。
- 被験者から単離した染色体DNAまたはそのmRNAと、請求項1のポリヌクレオチド、または請求項2のオリゴヌクレオチド、もしくはそれらの相補配列からなるポリヌクレオチドまたはオリゴヌクレオチドがストリンジェントな条件下でハイブリダイズするか否かを検出する請求項7の方法。
- 被験者から単離した染色体DNAまたはmRNAを鋳型とし、請求項3のプライマーセットを用いてPCRを行った場合のPCR産物の有無を検出する請求項7の方法。
- 男性不妊の検査方法であって、被験者から単離した生体試料中に請求項4のポリペプチドが存在するか否かを検出することを特徴とする方法。
- 被験者から単離した生体試料中に、請求項6の抗体と反応するポリペプチドが存在するか否かを検出する請求項10の方法。
- 請求項2のオリゴヌクレオチドを標識化したことを特徴とする男性不妊検査用DNAプローブ。
- 請求項2のオリゴヌクレオチドを含むことを特徴とする男性不妊検査用DNAチップ。
- 請求項6の抗体を標識化したことを特徴とする標識化抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008016852A JP4229973B2 (ja) | 2002-02-14 | 2008-01-28 | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002036649 | 2002-02-14 | ||
JP2002381241 | 2002-12-27 | ||
JP2008016852A JP4229973B2 (ja) | 2002-02-14 | 2008-01-28 | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003568082A Division JP4146353B2 (ja) | 2002-02-14 | 2003-02-14 | マウス精子形成遺伝子とヒト男性不妊関連遺伝子、ならびにこれらを用いた診断システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008154592A JP2008154592A (ja) | 2008-07-10 |
JP4229973B2 true JP4229973B2 (ja) | 2009-02-25 |
Family
ID=27736494
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003568082A Expired - Fee Related JP4146353B2 (ja) | 2002-02-14 | 2003-02-14 | マウス精子形成遺伝子とヒト男性不妊関連遺伝子、ならびにこれらを用いた診断システム |
JP2008016851A Expired - Fee Related JP4276691B2 (ja) | 2002-02-14 | 2008-01-28 | 男性不妊関連遺伝子プロタミン−2変異と男性不妊の診断方法 |
JP2008016852A Expired - Fee Related JP4229973B2 (ja) | 2002-02-14 | 2008-01-28 | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003568082A Expired - Fee Related JP4146353B2 (ja) | 2002-02-14 | 2003-02-14 | マウス精子形成遺伝子とヒト男性不妊関連遺伝子、ならびにこれらを用いた診断システム |
JP2008016851A Expired - Fee Related JP4276691B2 (ja) | 2002-02-14 | 2008-01-28 | 男性不妊関連遺伝子プロタミン−2変異と男性不妊の診断方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7842783B2 (ja) |
EP (1) | EP1484399A4 (ja) |
JP (3) | JP4146353B2 (ja) |
KR (2) | KR20070061926A (ja) |
CN (1) | CN1643148B (ja) |
CA (1) | CA2476561A1 (ja) |
WO (1) | WO2003068969A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010106788A1 (ja) | 2009-03-17 | 2010-09-23 | 凸版印刷株式会社 | 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008067649A (ja) * | 2006-09-14 | 2008-03-27 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、及びポリペプチド |
JP2008237114A (ja) * | 2007-03-27 | 2008-10-09 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、ポリペプチド、発現ベクター、及び発現キット |
CN101775372B (zh) * | 2009-12-02 | 2012-01-11 | 桂耀庭 | 一种抗睾丸hT279蛋白的抗体或抗体片段及其应用 |
CN101775371B (zh) * | 2009-12-02 | 2012-03-14 | 唐爱发 | 一种抗睾丸hTSC29蛋白的抗体或抗体片段及其应用 |
CN102262159B (zh) * | 2010-05-27 | 2014-03-26 | 李建远 | 用于检测生育相关人睾丸和附睾表达305种精子定位蛋白的方法 |
US9177098B2 (en) | 2012-10-17 | 2015-11-03 | Celmatix Inc. | Systems and methods for determining the probability of a pregnancy at a selected point in time |
US10162800B2 (en) | 2012-10-17 | 2018-12-25 | Celmatix Inc. | Systems and methods for determining the probability of a pregnancy at a selected point in time |
US9836577B2 (en) | 2012-12-14 | 2017-12-05 | Celmatix, Inc. | Methods and devices for assessing risk of female infertility |
KR102444117B1 (ko) | 2013-11-07 | 2022-09-16 | 오즈진 홀딩스 프로프라이어터리 리미티드 | 유전자 변형 동물을 생산하기 위한 조성물 및 방법 |
CN103743910B (zh) * | 2013-12-27 | 2015-11-18 | 上海市计划生育科学研究所 | Ctbs蛋白作为精卵结合受体的靶点在筛选精卵结合抑制剂中的应用 |
JP2017510250A (ja) * | 2014-01-27 | 2017-04-13 | セルマティックス, インコーポレイテッド | 遺伝的領域が、不妊に関連するか評価するための方法 |
CA2954895A1 (en) | 2014-07-17 | 2016-01-21 | Celmatix Inc. | Methods and systems for assessing infertility and related pathologies |
US10030241B2 (en) | 2015-03-30 | 2018-07-24 | General Electric Company | Methods and kits for capturing sperm nucleic acids |
US9957548B2 (en) | 2015-03-30 | 2018-05-01 | General Electric Company | Methods of capturing sperm nucleic acids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090555A (en) * | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
-
2003
- 2003-02-14 KR KR1020077011884A patent/KR20070061926A/ko not_active Application Discontinuation
- 2003-02-14 CN CN038061627A patent/CN1643148B/zh not_active Expired - Lifetime
- 2003-02-14 JP JP2003568082A patent/JP4146353B2/ja not_active Expired - Fee Related
- 2003-02-14 CA CA002476561A patent/CA2476561A1/en not_active Abandoned
- 2003-02-14 WO PCT/JP2003/001572 patent/WO2003068969A1/ja active Application Filing
- 2003-02-14 EP EP03705175A patent/EP1484399A4/en not_active Withdrawn
- 2003-02-14 KR KR1020047012460A patent/KR100828506B1/ko active IP Right Grant
- 2003-02-14 US US10/504,582 patent/US7842783B2/en not_active Expired - Fee Related
-
2008
- 2008-01-28 JP JP2008016851A patent/JP4276691B2/ja not_active Expired - Fee Related
- 2008-01-28 JP JP2008016852A patent/JP4229973B2/ja not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010106788A1 (ja) | 2009-03-17 | 2010-09-23 | 凸版印刷株式会社 | 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 |
US9194874B2 (en) | 2009-03-17 | 2015-11-24 | Toppan Printing Co., Ltd. | Test method for male fertility by detecting a mutation in the PGAM4 gene |
Also Published As
Publication number | Publication date |
---|---|
KR20040096564A (ko) | 2004-11-16 |
US20050176943A1 (en) | 2005-08-11 |
CA2476561A1 (en) | 2003-08-21 |
JP2008173125A (ja) | 2008-07-31 |
JP4276691B2 (ja) | 2009-06-10 |
CN1643148A (zh) | 2005-07-20 |
JP4146353B2 (ja) | 2008-09-10 |
WO2003068969A1 (en) | 2003-08-21 |
EP1484399A1 (en) | 2004-12-08 |
JP2008154592A (ja) | 2008-07-10 |
CN1643148B (zh) | 2011-04-20 |
KR20070061926A (ko) | 2007-06-14 |
EP1484399A4 (en) | 2006-04-05 |
JPWO2003068969A1 (ja) | 2005-06-02 |
US7842783B2 (en) | 2010-11-30 |
KR100828506B1 (ko) | 2008-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4229973B2 (ja) | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 | |
Janssen et al. | CIA30 complex I assembly factor: a candidate for human complex I deficiency? | |
US6787309B2 (en) | Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same | |
WO2009059317A2 (en) | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 | |
US20040132021A1 (en) | Osteolevin gene polymorphisms | |
US20180010190A1 (en) | Genetic variant of the annexin a5 gene | |
US20090269761A1 (en) | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof | |
KR101359851B1 (ko) | 간세포암종의 예후 진단용 단일 염기 다형성 | |
WO2013043041A2 (en) | Methods and compositions for diagnosing familial hypercholesterolemia | |
JP2002536961A (ja) | パーキン遺伝子の突然変異、組成物、方法及び使用 | |
US7081522B2 (en) | Gene causative of Rothmund-Thomson syndrome and gene product | |
Shim et al. | A novel mutation of the human 7-dehydrocholesterol reductase gene reduces enzyme activity in patients with holoprosencephaly | |
KR100790871B1 (ko) | 심근 경색에 관련된 유전자 다형성 및 그의 용도 | |
US7745121B2 (en) | Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer | |
JP4421889B2 (ja) | 慢性関節リウマチの発症危険度を予測する方法 | |
US7771942B2 (en) | Genetic marker for prostate cancer | |
JP2005073626A (ja) | 電子伝達フラビン蛋白脱水素酵素遺伝子の変異とそれを利用するグルタル酸尿症ii型の診断 | |
EP1264841A1 (en) | DNA encoding a mutant peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1), detection methods and test kits therefor | |
WO2012063829A1 (ja) | 新規遺伝子およびfong遺伝子座の一塩基多型に基づく骨粗鬆症の検査方法 | |
JP2009201364A (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081111 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4229973 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131212 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |